Marlissa Kit
Product Images NDC 68462-388

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Marlissa (NDC 68462-388). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glenmark Pharmaceuticals Inc., Usa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ctn

Packaging label for MARLISSA kit containing Levonorgestrel and Ethinyl Estradiol Tablets, USP 0.15 mg/0.03 mg. The kit includes 3 blisters, each containing 28 tablets. The label shows the product name, active ingredients with strengths, dosage form as a kit, and Glenmark Pharmaceuticals Inc., USA as the labeler. The front panel also notes the 28-day regimen and states the product is prescription only.*

FDA Label Image

Figure 2

A forest plot chart comparing 'Ever COC vs. Never COC Use' and 'Current COC use vs. Never-Use' across several studies. It shows effect estimates on a horizontal axis from -1.50 to 2.00 with values such as OR, RR, and HR for different studies, illustrating comparative risk or odds ratios with confidence intervals beside each point estimate.*

FDA Label Image

Figure1

A horizontal bar chart comparing the number of women with a blood clot per 10,000 women years (WY) across four groups: Non-Pregnant Non-COC users (ranges from 1 to 5), COC-Users (ranges from 3 to 9), Pregnancy (ranges from 5 to 20), and Postpartum (12 weeks only) with the highest range from 40 to 65. Pregnancy data is noted as based on actual pregnancy duration and model assumptions.*

FDA Label Image

Figurea

Diagram labeled Figure A showing a 4-week medication schedule for Levonorgestrel and Ethinyl Estradiol Tablets USP 0.15 mg/0.03 mg. It presents a grid with days of the week (Sunday to Saturday) across four rows labeled Start, Week 2, Week 3, and Week 4, each containing empty circles indicating daily tablet administration sequence with directional arrows.*

FDA Label Image

Logo

FDA Label Image

Structureee

Chemical structure of Ethinyl Estradiol, one of the active ingredients in MARLISSA (Levonorgestrel and Ethinyl Estradiol), depicted as a molecular diagram with labeled bonds and rings.*

FDA Label Image

Structurelevonorgestrel

Chemical structure of Levonorgestrel and Ethinyl Estradiol, the active ingredients in MARLISSA. The diagram depicts the molecular structure showing steroid backbone with functional groups characteristic of these hormones.*

FDA Label Image

Glenmark Logo (Image 05)

An illustration showing the relative effectiveness of various birth control methods arranged vertically by pregnancy rates per 100 women per year. Methods range from implants, injections, intrauterine devices, and sterilization (fewest pregnancies), followed by birth control pills, skin patch, and vaginal ring with hormones, then condoms and diaphragm, next behavioral and less effective methods such as no sex during fertile days, spermicide, withdrawal, and finally no birth control (most pregnancies).*

FDA Label Image

Image 08

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.